In a Phase 2 clinical trial, Biogen Idec and Roche reported their multiple sclerosis treatment, ocrelizumab, showed signs of reducing the disease indications – but they also reported that one patient died during the testing.

The drug, developed for patients with relapsing-remitting multiple sclerosis, showed a reduction in the number of flare-ups in a year and a reduction in brain lesions.

SOURCE